EUR/USD
1.17122
-0.067%
Gold
4597.41
-1.801%
Oil
97.435
2.649%
USD/JPY
159.592
0.110%
GBP/USD
1.35192
-0.103%
GBP/JPY
215.760
0.010%
Real-time News
April 29 - New research from the U.S. Geological Survey (USGS) indicates that the Appalachian region in the eastern United States contains enough lithium to reduce U.S. dependence on imports for centuries to come. The study shows that this area, covering Maine, New Hampshire, and the Carolinas, contains approximately 2.3 million tons of undiscovered, economically viable lithium deposits. This amount of lithium is enough to power 130 million electric vehicles or 1.6 million grid-scale batteries. Based on last years U.S. lithium imports, these reserves could replace 328 years of imports.The China Earthquake Networks Center automatically determined that an earthquake of approximately magnitude 5.0 occurred near Kuqa City, Aksu Prefecture, Xinjiang, at 03:16 on April 29. The final result is subject to the official rapid report.King Charles of Great Britain: The history of modern Anglo-American relations spans not just 250 years, but actually more than four centuries.On April 29, UAE Energy Minister Suhail al-Mazrouei stated in a media interview on the 28th that the UAEs decision to withdraw from the Organization of the Petroleum Exporting Countries (OPEC) at this time was primarily due to factors such as the current restrictions on passage through the Strait of Hormuz, and he believes this decision will have a limited impact on the global oil market. Mazrouei told CNN that the UAEs announcement of withdrawal was "timely" and would not have a significant impact on the oil market and prices, because of the restrictions on passage through the Strait of Hormuz, which also apply to the UAE. This decision will help alleviate price pressures.On April 29th, it was reported that the U.S. Food and Drug Administration (FDA) plans to shorten the time pharmaceutical companies need to test new drugs by increasing transparency in clinical trials. Jeremy Walsh, the agencys chief artificial intelligence officer, stated that this proposal could shorten drug development cycles by "months, or even years." Under the plan, the FDA will monitor macro-level signals regarding the effectiveness and safety of experimental drugs in real time, but will not collect all individual patient data. The FDA also issued a notice on Tuesday seeking information on how to use artificial intelligence to accelerate early-stage clinical research, which the FDA described as "a key bottleneck in drug development."
